Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of ligelizumab in Japanese chronic spontaneous urticaria
jRCT2080224633Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ligelizumab in chronic idiopathic urticaria (CIU), sponsored by Novartis. Primary endpoint: Safety and tolerability over 52 weeks. Started Apr 2019; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2080224633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224633.